Clinical Scorecard: Advancements in Oncolytic Virotherapy for Treating Pediatric Central Nervous System Tumors
At a Glance
Category
Detail
Condition
Pediatric central nervous system (CNS) tumors, including high-grade gliomas
Key Mechanisms
Selective infection and lysis of tumor cells by genetically engineered oncolytic viruses, induction of immunogenic tumor cell death, and activation of innate and adaptive immune responses
Target Population
Children with progressive or recurrent pediatric CNS tumors, especially high-grade gliomas
Care Setting
Specialized oncology centers with capability for intratumoral delivery and clinical trial participation
Key Highlights
Oncolytic herpes simplex viruses (oHSVs) such as G207 have demonstrated safety and preliminary efficacy in pediatric CNS tumor clinical trials.
oHSVs selectively replicate in tumor cells due to genetic modifications and tumor-specific cellular environments, sparing normal cells.
Intratumoral delivery of oHSV induces tumor cell lysis and promotes immune activation, converting immunologically 'cold' tumors to 'hot'.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of pediatric CNS tumor with histopathology and molecular profiling.
Assess tumor suitability for intratumoral oncolytic virotherapy based on tumor type and location.
Management
Consider intratumoral administration of oncolytic HSV (e.g., G207) in clinical trial settings for recurrent or progressive pediatric high-grade gliomas.
Combine oncolytic virotherapy with low-dose radiation (e.g., 5 Gy) to enhance viral replication and therapeutic efficacy.
Monitor for and manage mild toxicities; grade 1 adverse events are most commonly observed.
Monitoring & Follow-up
Perform serial imaging to evaluate radiographic tumor response.
Monitor clinical status and neurological function during and after treatment.
Assess immune response markers, including tumor-infiltrating lymphocytes and HSV-1 serostatus.
Risks
Potential for mild treatment-related toxicities; severe adverse events have not been reported in trials to date.
Uncertain impact of baseline HSV-1 seropositivity on treatment outcomes; requires cautious interpretation.
Patient & Prescribing Data
Children aged 7 to 18 years with progressive or recurrent pediatric high-grade gliomas enrolled in clinical trials
G207 administered intratumorally at doses up to 10⁸ PFU is safe and shows encouraging median overall survival (12.2 months) compared to historical controls (5.6 months). Combining with radiation may improve efficacy. Immune activation correlates with clinical response.
Clinical Best Practices
Use stereotactic placement of intratumoral catheters for precise delivery of oncolytic virus.
Employ continuous infusion over several hours to optimize viral distribution within the tumor.
Incorporate immune monitoring to evaluate treatment-induced tumor microenvironment changes.
Select patients carefully for clinical trial enrollment based on tumor characteristics and prior therapies.
by Amr Elgehiny, Aaron E. Fan, Maria Frost, Jiasen He, Sam E. Gary, Diana S. Osorio, Wafik Zaky, Li Zhou, Kyung-Don Kang, Zhuo Zhang, Juan Fueyo, Candelaria Gomez-Manzano, Eric M. Thompson, Joshua D. Bernstock, Gregory K. Friedman
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.
